ライフサイエンスコーパス: mycoses

1 ompromised patients only, except for endemic mycoses.

2 (TLR9) can control cryptococcosis and other mycoses.

3 ties for improving outcomes from HIV-related mycoses.

4 e further developed for use against invasive mycoses.

5 being occasional agents of human and animal mycoses.

6 exception of M. furfur and possibly endemic mycoses.

7 dioidomycosis and meningitis caused by other mycoses.

8 auses of pneumonia, including other invasive mycoses.

9 l therapy for patients with life-threatening mycoses.

10 f interferon-gamma immunity underlie endemic mycoses.

11 portant fungal pathogens that cause invasive mycoses.

12 se of the assay in diagnosing other invasive mycoses.

13 gs used in treatment of topical and systemic mycoses.

14 B is the gold standard treatment for severe mycoses.

15 fungus that causes life-threatening systemic mycoses.

16 tical gaps in the management of AIDS-related mycoses.

17 to blastomycosis, which is similar to other mycoses and has parallels in humans.

18 lus mould infections, several of the endemic mycoses and serious Candida infections.

19 adily with the rise and fall of AIDS-related mycoses, and the change in spectrum of fatal disseminate

20 drugs approved for the treatment of invasive mycoses, and the efficacy of these agents is compromised

21 the current state of the-art in AIDS-related mycoses, and the key action points required to improve o

22 These findings highlight that serious mycoses are a relevant but under-recognized health probl

23 nto account when vaccines to protect against mycoses are designed.

24 Pulmonary mycoses are difficult to treat and detrimental to patien

25 Pulmonary mycoses are increasingly encountered in children with un

26 Cutaneous implantation and systemic mycoses are neglected diseases that affect millions of i

27 nclusion, fusaria associated with veterinary mycoses are phylogenetically diverse and typically can o

28 , options for clinical interventions for CNS mycoses are still limited.

29 equiseti species complex (FIESC), with eight mycoses-associated species, may represent the second mos

30 (5-FC) is used for the treatment of several mycoses, but is unsuitable for monotherapy due to the ra

31 dermatophytosis, pneumocystosis, and endemic mycoses can all be caused by PIDs.

32 e epidemiology and pathogenesis of pulmonary mycoses can be applied to prevent infection in many case

33 report the first two cases of invasive human mycoses caused by the phaeoid ascomycete, Chaetomium per

34 At the second EMBO Workshop on AIDS-Related Mycoses, clinicians and scientists from around the world

35 igen testing in the diagnosis of the endemic mycoses.Conclusions: Rapid, accurate diagnosis of fungal

36 The dimorphic mycoses (DMs) of the United States-Histoplasma, Coccidio

37 le macrophages are essential for controlling mycoses due to Cryptococcus spp., Histoplasma spp., and

38 rium species associated with human or animal mycoses encountered in clinical microbiology laboratorie

39 host-pathogen interaction mechanisms in CNS mycoses for developing novel treatments.

40 Invasive mycoses have become important causes of morbidity and mo

41 erited human susceptibility to opportunistic mycoses have significantly expanded our understanding of

42 reasing resistance could impact treatment of mycoses in general and infectious fungal keratitis in pa

43 ith micafungin or ABLC decreased the risk of mycoses in high-risk recipients compared with that in lo

44 is causes one of the most prevalent systemic mycoses in Latin America--paracoccidioidomycosis.

45 ristii is a significant cause of respiratory mycoses in North America with occasional reported outbre

46 to protect against the three major systemic mycoses in North America.

47 ryptococcosis is a significant opportunistic mycoses in organ transplant recipients.

48 stantial and heterogeneous burden of serious mycoses in Poland.

49 fluconazole administration for prevention of mycoses in SICU patients appears to successfully decreas

50 egies for preventing and treating refractory mycoses in the future.

51 vel therapeutic strategies for opportunistic mycoses in transplant recipients.

52 us complications, such as those from endemic mycoses, in patients receiving treatment with a TNF-alph

53 Rare instances of aspergillosis and other mycoses, including agents of mucormycosis may also be tr

54 The incidence of mycoses is rising because of the HIV pandemic and becaus

55 heir effectiveness in the treatment of human mycoses is to be determined.

56 its effectiveness in the treatment of human mycoses is under evaluation in clinical trials.

57 )/International Society for Human and Animal Mycoses (ISHAM) criteria.

58 e International Society for Human and Animal Mycoses (ISHAM), FDIG hosted a forum highlighting key ch

59 onia, aspergillosis, candidemia, and endemic mycoses; lack of a standardized molecular approach to id

60 kers convened for the triennial AIDS-Related Mycoses Meeting to address critical gaps in the manageme

61 eviews the changing epidemiology of invasive mycoses, new diagnostic methods, and recent therapeutic

62 inding of this study is that FSSC-associated mycoses of humans and other animals have origins in a br

63 s, and Blastomyces-commonly known as endemic mycoses of North America (in addition to Paracoccidioide

64 an off-patent antifungal agent used to treat mycoses of skin and nails, has recently been demonstrate

65 implicated as the causative agents of human mycoses, particularly in the expanding immunocompromised

66 Invasive mycoses pose a major diagnostic and therapeutic challeng

67 Mycoses range from life-threatening, often iatrogenic co

68 nosocomial infection and a leading cause of mycoses-related deaths.

69 Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC) definition and analyzed surv

70 Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) consensus definitions (1

71 Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) consensus definitions (1

72 ion for the Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) criteria.

73 sive Fungal Infections Cooperative Group and Mycoses Study Group (EORTC/MSG) criteria.

74 Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) definitions for fungal d

75 ion for the Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) definitions of invasive

76 Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) definitions, and 6-week

77 Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG)-defined hematological po

78 ngal infections (IFI) according to EORTC and Mycoses Study Group (MSG) definitions.

79 isation for Research and Treatment of Cancer/Mycoses Study Group 2008 criteria) attributed to healthc

80 ization for Research and Treatment of Cancer/Mycoses Study Group consensus definitions, by direct det

81 ean Organization for the treatment of Cancer/Mycoses Study Group criteria as a reference standard.

82 ization for Research and Treatment of Cancer/Mycoses Study Group criteria classified these as "probab

83 for Research and Treatment in Cancer and the Mycoses Study Group criteria in a cohort study at our ce

84 nization of Research and Treatment of Cancer/Mycoses Study Group criteria modified for patients with

85 ion for Research and Treatment of Cancer and Mycoses Study Group criteria) in hemato-oncological pati

86 ion for the Research and Treatment of Cancer/Mycoses Study Group criteria, 32 patients had probable a

87 ization for Research and Treatment of Cancer/Mycoses Study Group criteria.

88 Institute of Allergy and Infectious Diseases Mycoses Study Group criteria.

89 isation for Research and Treatment of Cancer/Mycoses Study Group definition criteria were applied and

90 isation for Research and Treatment of Cancer-Mycoses Study Group definition of proven PCP was examine

91 for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium (E

92 for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium (E

93 for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium (E

94 ion for the Research and Treatment of Cancer/Mycoses Study Group Education and Research Consortium (E

95 for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium co

96 ion for Research and Treatment of Cancer and Mycoses Study Group Education and Research Consortium de

97 sourced call for cases solicited through the Mycoses Study Group Education and Research Consortium, t

98 rdisciplinary expert panel of members of the Mycoses Study Group Education and Research Consortium.

99 for Research and Treatment of Cancer and the Mycoses Study Group have been of immense value to resear

100 ization for Research and Treatment of Cancer/Mycoses Study Group in 2008, we recategorized the 379 ep

101 Invasive Fungal Infections Cooperative Group/Mycoses Study Group of the National Institute of Allergy

102 agnosis and management were developed by the Mycoses Study Group Research Education and Consortium (M

103 ion for the Research and Treatment of Cancer/Mycoses Study Group.

104 The 2008 Mycoses Study Group/European Organization for the Resear

105 oculation, several fungi can cause neglected mycoses such as sporotrichosis, chromoblastomycosis, myc

106 Other mycoses, such as keratitis and subcutaneous forms, are r

107 aluated the RID-MyC (Rapid Identification of Mycoses using clustered regularly interspaced short pali

108 invasive candidiasis, and the common endemic mycoses was systematically reviewed.

109 urements involving 55 patients with invasive mycoses who received recommended VRC doses.

110 The only mycoses with common central nervous system (CNS) involve

111 This review, based on the EMBO AIDS-Related Mycoses Workshop in Cape Town in July 2013, summarizes t

112 The third AIDS-related mycoses workshop updated progress in the field over the